SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-002423
Filing Date
2024-01-04
Accepted
2024-01-04 16:01:31
Documents
15
Period of Report
2023-12-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d669255d8k.htm   iXBRL 8-K 30894
2 EX-10.1 d669255dex101.htm EX-10.1 40402
3 EX-10.2 d669255dex102.htm EX-10.2 18930
4 EX-10.3 d669255dex103.htm EX-10.3 36324
  Complete submission text file 0001193125-24-002423.txt   288226

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA pstx-20231231.xsd EX-101.SCH 2837
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20231231_lab.xml EX-101.LAB 18736
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20231231_pre.xml EX-101.PRE 11698
9 EXTRACTED XBRL INSTANCE DOCUMENT d669255d8k_htm.xml XML 3478
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 24511718
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)